Skip to main content

Table 4 Clinical outcomes according to the use of RAAS blockers

From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19

Clinical outcome

Antihypertensive treatment

(n = 1,044)

ACEI/ARB

(n = 782)

Non-ACEI/ARB

(n = 262)

Unadjusted

Age, sex-adjusted

Multivariable adjusted

OR (95 % CI)

P-value

OR (95 % CI)

P-value

OR (95 % CI)

P-value

Hospitalization

540 (51.7)

389 (49.7)

151 (57.6)

1.05 (0.83–1.33)

0.691

1.13 (0.89–1.45)

0.320

1.16 (0.90–1.49)

0.263

Oxygen requirement

142 (13.6)

97 (12.4)

45 (17.2)

0.87 (0.61–1.24)

0.445

0.96 (0.67–1.37)

0.802

0.96 (0.67–1.38)

0.813

Severe outcome

76 (7.3)

49 (6.3)

27 (10.3)

0.58 (0.36–0.95)

0.031

0.66 (0.40–1.09)

0.104

0.68 (0.41–1.15)

0.150

   ICU admission

33 (3.2)

20 (2.6)

13 (5.0)

0.57 (0.30–1.09)

0.084

0.60 (0.31–1.16)

0.127

0.61 (0.32–1.18)

0.139

   Ventilator care

21 (2.0)

12 (1.5)

9 (3.4)

0.47 (0.21–1.05)

0.059

0.51 (0.23–1.14)

0.101

0.48 (0.21–1.08)

0.076

   Death

54 (5.2)

35 (4.5)

19 (7.3)

0.69 (0.41–1.16)

0.161

0.78 (0.45–1.33)

0.358

0.75 (0.43–1.30)

0.302

  1. Data are presented as number (%) unless otherwise specified
  2. RAAS renin-angiotensin-aldosterone-system, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, ICU intensive care unit, OR odds ratios, CI confidence intervals